Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report

被引：0
|
作者：
Centrone, Renato [1 ]
Bellesso, Marcelo [1 ]
Bonito, Debora [2 ]
Dias, Daniela [1 ]
Santucci, Rodrigo [1 ]
Aranha, Milton [1 ]
Alves, Adelson [1 ]
机构：
[1] Inst Hemomed Oncol & Hematol, Av Arnolfo Azevedo 108, BR-01236030 Sao Paulo, SP, Brazil
[2] Fac Med ABC, Sao Paulo, SP, Brazil
来源：
HEMATOLOGY TRANSFUSION AND CELL THERAPY | 2020年 / 42卷 / 04期
关键词：
DIAGNOSED CHRONIC-PHASE; FOLLOW-UP; THERAPY;
D O I：
10.1016/j.htct.2019.09.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：373 / 375
页数：3
相关论文
共 50 条
  • [1] Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia
    Pungolino, Ester
    D'adda, Mariella
    Perego, Alessandra
    Orlandi, Ester Maria
    Turrini, Mauro
    Borin, Lorenza Maria
    Iurlo, Alessandra
    Artale, Salvatore
    Latargia, Maria Luisa
    Anghilieri, Michela
    Malato, Simona
    Trojani, Alessandra
    Spina, Francesco
    Cristina, Carraro Maria
    Pioltelli, Maria Luisa
    Elena, Chiara
    Bucelli, Cristina
    Spedini, Pierangelo
    Rossi, Giuseppe
    Morra, Enrica
    Cairoli, Roberto
    BLOOD, 2017, 130
  • [2] Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: A case report
    Caocci G.
    Greco M.
    La Nasa G.
    Journal of Medical Case Reports, 8 (1)
  • [3] Nilotinib As Second-Line Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase: Thailand Experience
    Chansung, Kanchana
    Sirijerachai, Chittima
    Lekhakula, Arnuparp
    Viboonjuntra, Pongtep
    Niparuck, Pimjai
    Pauvilai, Teeraya
    Numbenjapon, Tontanai
    Bunworasate, Udomsak
    Nawarawong, Weerasak
    Tantiworawit, Adisak
    Suwanban, Tawatchai
    Jootar, Saengsuree
    BLOOD, 2016, 128 (22)
  • [4] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Guoqing Wei
    Shamudheen Rafiyath
    Delong Liu
    Journal of Hematology & Oncology, 3
  • [5] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Wei, Guoqing
    Rafiyath, Shamudheen
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
  • [6] Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia
    Gugliotta, Gabriele
    Castagnetti, Fausto
    Breccia, Massimo
    Gozzini, Antonella
    Usala, Emilio
    Carella, Angelo M.
    Rege-Cambrin, Giovanna
    Martino, Bruno
    Abruzzese, Elisabetta
    Albano, Francesco
    Stagno, Fabio
    Luciano, Luigia
    D'Adda, Mariella
    Bocchia, Monica
    Cavazzini, Francesco
    Tiribelli, Mario
    Lunghi, Monia
    Falcone, Antonietta Pia
    Musolino, Caterina
    Levato, Luciano
    Venturi, Claudia
    Soverini, Simona
    Cavo, Michele
    Alimena, Giuliana
    Pane, Fabrizio
    Martinelli, Giovanni
    Saglio, Giuseppe
    Rosti, Gianantonio
    Baccarani, Michele
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (06) : 617 - 622
  • [7] Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report
    Sachdeva, Meenakshi
    Singh, Jayanti
    Dayal, Surabhi
    Gupta, Aanchal
    INDIAN DERMATOLOGY ONLINE JOURNAL, 2024, 15 (03) : 492 - 495
  • [8] Nilotinib: A Case of Acute Pancreatitis in a Patient With Chronic Myeloid Leukemia
    Patel, Vihang
    Attia, Karim
    Pattisapu, Anil
    Weiss, John
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S56 - S56
  • [9] THE BUDGET IMPACT ANALYSIS OF NILOTINIB IN THE SECOND-LINE TREATMENT OF IMATINIB-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA
    Huang, C.
    Shen, L.
    Liu, Y.
    VALUE IN HEALTH, 2018, 21 : S96 - S96
  • [10] Imatinib-rifampicin interaction in chronic myeloid leukemia patient: case report
    El Ferjani, S.
    Sahnoun, R.
    Gaies, E.
    Charfi, R.
    Jebabli, N.
    Salouage, I.
    Lakhal, M.
    Trabelsi, S.
    Klouz, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 93 - 93
12345